Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 26,222 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Patient Clear all
Terminated No phase listed Observational

Serial Testing To Assess Cognitive Function In Cancer

NCT06160700
View directory record Official record
Conditions
Cancer
Interventions
Montreal Cognitive Assessment (MoCA)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00962507
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)

NCT04492007
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 20, 2026, 1:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03661307
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

NCT04439227
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Adavosertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

NCT02391727
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Interventions
SYN004
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New Orleans, Louisiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 20, 2026, 1:38 PM EDT
Not listed Phase 1 Interventional

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

NCT00003073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
liposomal cytarabine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight

NCT01828554
View directory record Official record
Conditions
Obesity, Neoplasms
Interventions
Xeloda
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 20, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

NCT06898905
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bridging Radiation Therapy
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Nivolumab, cabiralizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

NCT03517956
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
Rogaratinib (BAY1163877), Copanlisib (BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medical Physics Direct Patient Care for the Improvement of Patient Understanding of Care

NCT04266522
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Informational Intervention, Counseling, Questionnaire Administration
Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 20, 2026, 1:38 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness

NCT06630351
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Behavioral Counseling, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Prospective Analysis to Detect Myometrial Cells in Peritoneal Washing in Patients Undergoing Minimally Invasive Hysterectomy Using Containment Bag at University of Texas Medical Branch

NCT05955651
View directory record Official record
Conditions
Hysterectomy
Interventions
Peritoneal washings
Diagnostic Test
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 20, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

NCT03884829
View directory record Official record
Conditions
AML, Adult, Myelodysplastic Syndromes, ALL, Adult, CML, Refractory, CLL, Refractory
Interventions
CYC140
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Study of TCP-ATRA for Adult Patients With AML and MDS

NCT02273102
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
Interventions
Tranylcypromine, Tretinoin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953
View directory record Official record
Conditions
Abdominal Neoplasms, Pelvic Neoplasms
Interventions
Optison
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537
View directory record Official record
Conditions
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
Interventions
rigosertib sodium
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

NCT00129337
View directory record Official record
Conditions
Tumors
Interventions
Bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Tucson, Arizona • Santa Monica, California • Memphis, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational Results available

Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device

NCT01944345
View directory record Official record
Conditions
Prolapsed Lumbar Disc, Prolapsed Cervical Disc, Intervertebral Disc Degeneration, Spondylolisthesis, Grade 1, Intervertebral Disc Displacement
Interventions
Not listed
Lead sponsor
Wenzel Spine
Industry
Eligibility
18 Years to 99 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 20, 2026, 1:38 PM EDT
Terminated No phase listed Observational

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

NCT05052372
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Transitional Cell Carcinoma, Platinum-Resistant Urothelial Carcinoma, Bladder Urothelial Carcinoma, FGFR Mutation, FGFR2 Gene Mutation, FGFR3 Gene Mutation, FGFR2 Amplification, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Carcinoma, Refractory Bladder Urothelial Carcinoma
Interventions
Balversa
Drug
Lead sponsor
xCures
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 20, 2026, 1:38 PM EDT
Not yet recruiting Phase 3 Interventional

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

NCT07842172
View directory record Official record
Conditions
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Interventions
Somatostatin Analogue(s)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795
View directory record Official record
Conditions
Multiple Myeloma
Interventions
isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC, Investigational injector device
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Gilbert, Arizona • Duarte, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 20, 2026, 1:38 PM EDT